Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median ...
Several companies have issued product recalls for items posing safety risks, according to announcements made on. Consumers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback